Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $374.0 million.

  • Dianthus Therapeutics' Liabilities and Shareholders Equity rose 63.01% to $577.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 26.54%. This contributed to the annual value of $374.0 million for FY2024, which is 108.47% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Liabilities and Shareholders Equity of $374.0 million as of FY2024, which was up 108.47% from $179.4 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Liabilities and Shareholders Equity registered a high of $374.0 million during FY2024, and its lowest value of $83.1 million during FY2022.
  • In the last 3 years, Dianthus Therapeutics' Liabilities and Shareholders Equity had a median value of $179.4 million in 2023 and averaged $212.2 million.
  • Data for Dianthus Therapeutics' Liabilities and Shareholders Equity shows a peak YoY soared of 115.86% (in 2023) over the last 5 years.
  • Dianthus Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $83.1 million in 2022, then surged by 115.86% to $179.4 million in 2023, then skyrocketed by 108.47% to $374.0 million in 2024.